Loading
A phase 1/2 trial of DJI136 in small-cell lung cancer, run by Novartis Pharmaceuticals, now recruiting.
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy is a phase 1/2 interventional study registered as NCT07564401 by Novartis Pharmaceuticals, with 80 participants planned, started 2026-06-16 and due to reach its primary completion in 2031-03-03. Interventions recorded: DJI136. Conditions listed: Extensive-stage Small Cell Lung Cancer (ES-SCLC). No results are recorded here; the registry entry is the source.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Novartis, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Novartis, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer.